ResMed (RMD) Revenue — Quarter Ended Sep 30, 2024
Revenue for the quarter increased compared with both the prior quarter and the same quarter a year earlier. The year-over-year growth was notably stronger than the sequential change.
Key takeaway
Quarter ended Sep 30, 2024 · FY2025 Q1
Revenue for the quarter increased compared with both the prior quarter and the same quarter a year earlier. The year-over-year growth was notably stronger than the sequential change.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.2B
Revenue reported for this quarter.
Quarter-over-quarter
+0.1%
Change from the immediately preceding quarter.
Year-over-year
+11.1%
Change from the comparable year-ago quarter.
Trailing four quarters
$4.8B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $1.2B | +12.5% |
| Mar 31, 2024 | $1.2B | +7.2% |
| Jun 30, 2024 | $1.2B | +9.0% |
| Sep 30, 2024 | $1.2B | +11.1% |
Revenue performance
Reported revenue rose from the immediately preceding quarter, continuing an upward trajectory. The year-over-year comparison showed a more pronounced increase, reflecting sustained expansion.
Quarterly comparison
Sequentially, revenue edged higher, while the year-over-year gain was substantially larger. This pattern indicates a stronger performance relative to the same period last year than to the prior quarter.
What to watch
The filing context mentions potential fluctuations in operating cash flow due to supply chain disruptions and working capital requirements.